Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • GBMA Executive and Board
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
        • 2022
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • International Generic and Biosimilar Medicines Association (IGBA)
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2023
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / GBMA Code of Practice / Annual Review / 2011

2011

The Generic Medicines Industry Association (GMiA) is pleased to announce the completion of its Code of Practice review for 2011.   The review indicates that the Code has been effective in formalising the high standards of conduct adhered to by its Members.

Pursuant to section 15 of the Code, the Code Administration Committee was convened in September 2011 to ensure the successful implementation and ongoing effectiveness of the Code. The Committee prepared its annual report for the GMiA Board. This report is posted below.

 

imagesCANP5FVD  GMiA Code of Practice Review October 2011

 

 

As set out in section 13 of the Code, an Independent Reviewer has reviewed the Educational Event Reports submitted by Members and conducted spot audits of Members’ marketing and promotional material to determine compliance with the Code.  The Independent Reviewer concluded that there was nothing to indicate any level of non-compliance by Members. The Independent Reviewer’s report is posted below.
imagesCANP5FVD  Independent Review Report October 2011

Our Members

Sandoz Logo
Sandoz Logo Sandoz Blue RGB
PRIMARY_neo_health_logo_RGB[86]
PRIMARY_neo_health_logo_RGB[86]
logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Gedeon_Richter_HOR_CMYK-01
Gedeon_Richter_HOR_CMYK-01
Juno
Juno
Teva
Teva
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
CommEyes_Logo_Full (3)
CommEyes_Logo_Full (3)
sinapse
sinapse
PearceIP-Masterbrand-CMYK-tag
PearceIP-Masterbrand-CMYK-tag

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care

November 14, 2023

Tuesday, November 14, 2023 Geneva, Switzerland In the week … More...

Neo Health joins GBMA under new membership tier

September 28, 2023

Thursday, September 28, 2023 Canberra, … More...

GBMA welcomes Teva Pharma to its growing membership base

July 24, 2023

Tuesday July 25, 2023 Canberra, … More…

© 2023 Generic and Biosimilar Medicines Association Pty Ltd | Privacy Policy | Contact Us